Vitestro Raises $70 Million in Series B Financing

Vitestro has closed a $70 million oversubscribed Series B funding round that drew support from both new and existing investors.

Financial assistance came from Labcorp Venture Fund, Mayo Clinic, and Sutter Health, new investors InterVest, MGFO, PGGM, Puma Venture Capital, and ROM Utrecht, and continued support from existing backers Invest-NL (supported by InvestEU), EIC Fund, Fred Moll, NYBC Ventures, and Sonder Capital.

Vitestro plans to use the money to advance the next-generation Aletta Autonomous Robotic Phlebotomy Device (ARPD), enabling deeper integration into high-volume clinical workflows. The funding will also support Vitestro’s U.S. Food and Drug Administration (FDA) De Novo regulatory pathway and global commercial readiness, including manufacturing scale-up, clinical expansion, and commercial infrastructure development, as the company prepares for broader market adoption beginning in Europe and progressing toward the U.S. market.

“Closing our Series B financing reflects strong conviction in our mission to establish a new standard in autonomous robotic venous access and diagnostic blood collection,” Vitestro Co-Founder/CEO Toon Overbeeke stated. “Our technology has evolved from a novel vision into a clinically validated reality, and we are grateful for the support of this syndicate of strategic, healthcare, and life science investors as we move toward broad clinical adoption. Diagnostic blood collection remains the highest-volume invasive medical procedure globally, with billions of procedures performed annually.”

Vitestro leadership will use the proceeds to further advance the platform’s technical capabilities and integration into existing technology infrastructure, conduct essential clinical studies and pilot programs to embed the technology into real-world workflows, and expand its team to meet growing demand from healthcare providers.

“The Labcorp Venture Fund sees strong potential in solutions that modernize core diagnostic processes and improve consistency for patients,” Labcorp Venture Fund head Megann Vaughn Watters said. “Applying robotics, multimodal imaging, and AI to clinically validated diagnostic blood collection is an exciting approach, and we’re thrilled to support Vitestro as they advance this important work.”

The Aletta ARPD is designed to autonomously perform diagnostic blood collection. The system combines multimodal imaging, advanced robotics, and artificial intelligence to identify suitable veins, guide needle insertion, and collect blood samples with high precision and consistency. Aletta supports phlebotomy departments by performing routine diagnostic blood draws, helping address staffing challenges, reducing human-dependent variability, standardizing quality, enhancing the overall patient experience, and enabling greater operational predictability and scalability in high-volume outpatient care settings.

“Vitestro is redefining one of the largest and most under innovated clinical workflows with a first-of-its-kind autonomous robotic platform for diagnostic blood collection addressing an enormous unmet global market need,” said Dr. Fred Moll, co-founder and partner at Sonder Capital and former co-founder and CEO of Intuitive Surgical and Auris Health. “I believe this technology has the potential to establish a new standard of care, much as robotic surgery did in its early days.”

Vitestro is a global developer of medical robotics that advances diagnostic blood collection through autonomous technology. Headquartered in the Netherlands, the company has expertise in engineering, robotics, artificial intelligence, and commercialization. Vitestro has developed Aletta, reportedly the world’s first and only CE-marked Autonomous Robotic Phlebotomy Device (ARPD), establishing a new category and benchmark for diagnostic blood collection. By integrating advanced robotics, multimodal imaging, and AI, Vitestro is enabling greater precision, operational efficiency, and an improved patient experience in clinical settings. Aletta is currently CE-marked and is currently being deployed in clinical and pre-commercial settings in Europe and has not yet been authorized in the United States. Vitestro is actively advancing its U.S. regulatory pathway while expanding global clinical collaborations to support the future commercialization of autonomous diagnostic blood collection worldwide.